Abstract
Endovascular management of superficial femoral artery disease has historically been limited to percutaneous balloon angioplasty, atherectomy, and bare-metal stents. However, these therapies have been plagued by high restenosis and target lesion revascularization rates. More recent technologies such as drug-coated stents and balloons are designed to combat restenosis by locally delivering antiproliferative drugs. Several randomized controlled trials have directly compared these antiproliferative drug-delivering devices to their non-drug-coated counterparts. Additionally, trials are currently ongoing to compare use of drug-coated technologies in combination with traditional therapies in hope of synergistic effects. This review gathers data from currently published clinical trials, provides an overview of upcoming clinical studies utilizing drug-coated technology, and explores the possible impact these devices may have on clinical practice.
| Original language | English (US) |
|---|---|
| Journal | Current Cardiology Reports |
| Volume | 17 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2015 |
Fingerprint
Keywords
- Chronic total occlusion
- Drug-coated balloons
- Drug-coated stents
- Endovascular revascularization
- Peripheral artery disease
- Superficial femoral artery
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Drug-Coated Balloon and Stent Therapies for Endovascular Treatment of Atherosclerotic Superficial Femoral Artery Disease. / Banerjee, Subhash; Sarode, Karan; Mohammad, Atif; Brilakis, Emmanouil S.
In: Current Cardiology Reports, Vol. 17, No. 5, 01.05.2015.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Drug-Coated Balloon and Stent Therapies for Endovascular Treatment of Atherosclerotic Superficial Femoral Artery Disease
AU - Banerjee, Subhash
AU - Sarode, Karan
AU - Mohammad, Atif
AU - Brilakis, Emmanouil S.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Endovascular management of superficial femoral artery disease has historically been limited to percutaneous balloon angioplasty, atherectomy, and bare-metal stents. However, these therapies have been plagued by high restenosis and target lesion revascularization rates. More recent technologies such as drug-coated stents and balloons are designed to combat restenosis by locally delivering antiproliferative drugs. Several randomized controlled trials have directly compared these antiproliferative drug-delivering devices to their non-drug-coated counterparts. Additionally, trials are currently ongoing to compare use of drug-coated technologies in combination with traditional therapies in hope of synergistic effects. This review gathers data from currently published clinical trials, provides an overview of upcoming clinical studies utilizing drug-coated technology, and explores the possible impact these devices may have on clinical practice.
AB - Endovascular management of superficial femoral artery disease has historically been limited to percutaneous balloon angioplasty, atherectomy, and bare-metal stents. However, these therapies have been plagued by high restenosis and target lesion revascularization rates. More recent technologies such as drug-coated stents and balloons are designed to combat restenosis by locally delivering antiproliferative drugs. Several randomized controlled trials have directly compared these antiproliferative drug-delivering devices to their non-drug-coated counterparts. Additionally, trials are currently ongoing to compare use of drug-coated technologies in combination with traditional therapies in hope of synergistic effects. This review gathers data from currently published clinical trials, provides an overview of upcoming clinical studies utilizing drug-coated technology, and explores the possible impact these devices may have on clinical practice.
KW - Chronic total occlusion
KW - Drug-coated balloons
KW - Drug-coated stents
KW - Endovascular revascularization
KW - Peripheral artery disease
KW - Superficial femoral artery
UR - http://www.scopus.com/inward/record.url?scp=84928626959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928626959&partnerID=8YFLogxK
U2 - 10.1007/s11886-015-0586-8
DO - 10.1007/s11886-015-0586-8
M3 - Article
C2 - 25894799
AN - SCOPUS:84928626959
VL - 17
JO - Current Cardiology Reports
JF - Current Cardiology Reports
SN - 1523-3782
IS - 5
ER -